Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Odronextamab in Low Tumor Volume Advanced FL

The purpose of this study is to evaluate the safety and effectiveness of treating previously untreated Follicular Lymphoma (FL) with odronextamab. The name of the study drug in this research study is: -Odronextamab (a type of monoclonal antibody)

Participants needed: 35
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Gottfried von Keudell, MD PhDUpdated: Mar 13, 2026Locations: 1
Eligibility criteria

Biopsy-confirmed (fresh or archival tissue) follicular lymphoma grade 1-3A that... [+29]

Participants must not meet any GELF Criteria for high tumor volume, or other cir... [+27]

Status: Recruiting

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma (MZL). The names of the study drugs involved in this study are: * Venetoclax (a type of inhibitor) * Rituximab (a type of antibody)

Participants needed: 33
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Gottfried von Keudell, MD PhDUpdated: Mar 13, 2026Locations: 1
Eligibility criteria

Participants must have histologically confirmed Marginal Zone Lymphoma [+17]

Patients who had prior systemic therapy including rituximab [+10]

Status: Recruiting

Epcoritamab in Previously Treated WM

This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM). The names of the study drug involved in this study is: -Epcoritamab (a type of antibody)

Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Gottfried von Keudell, MD PhDUpdated: Mar 13, 2026Locations: 3
Eligibility criteria

A diagnosis of lymphoplasmacytic lymphoma/WM that is CD20+ by immunophenotype or... [+25]

Participants who have disease that has transformed to aggressive lymphoma [+16]